Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$696M |
| 2 |
AABA
Altaba Inc
AABA
|
+$632M |
| 3 |
AT&T
T
|
+$433M |
| 4 |
Goldman Sachs
GS
|
+$392M |
| 5 |
Walt Disney
DIS
|
+$384M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.5B |
| 2 |
Apple
AAPL
|
+$1.26B |
| 3 |
Amazon
AMZN
|
+$1B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$938M |
| 5 |
Netflix
NFLX
|
+$423M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 92.29% |
| 2 | Technology | 1.9% |
| 3 | Financials | 1.28% |
| 4 | Communication Services | 1.02% |
| 5 | Consumer Discretionary | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3726
State Street SPDR Portfolio Mortgage Backed Bond ETF
SPMB
$7.12B
| $2.34M | ﹤0.01% |
+92,281
| New | +$2.34M |
|
|
MYOK
3727
PUT
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.33M | ﹤0.01% |
47,000
-65,400
| -58% | -$3.17M |
|
3728
PUT
Natural Health Trends
NHTC
$13.7M
| $2.33M | ﹤0.01% |
93,200
-145,400
| -61% | -$3.04M |
|
|
RP
3729
PUT
DELISTED
RealPage, Inc.
RP
| $2.33M | ﹤0.01% |
42,300
+37,900
| +861% | +$2.14M |
|
3730
CALL
Aramark
ARMK
$15.3B
| $2.33M | ﹤0.01% |
86,978
+23,683
| +37% | +$655K |
|
|
SGYP
3731
PUT
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $2.33M | ﹤0.01% |
1,338,600
-373,900
| -22% | -$646K |
|
|
COR
3732
CALL
DELISTED
Coresite Realty Corporation
COR
| $2.33M | ﹤0.01% |
21,000
+3,200
| +18% | +$338K |
|
3733
PUT
Argan
AGX
$5.86B
| $2.32M | ﹤0.01% |
56,700
-13,800
| -20% | -$538K |
|
|
IPCC
3734
DELISTED
Infinity Property & Casualty C
IPCC
| $2.32M | ﹤0.01% |
16,307
-4,291
| -21% | -$581K |
|
3735
PUT
Corcept Therapeutics
CORT
$12.3B
| $2.32M | ﹤0.01% |
147,600
-17,500
| -11% | -$304K |
|
3736
PUT
Intellia Therapeutics
NTLA
$1.8B
| $2.32M | ﹤0.01% |
84,700
-130,200
| -61% | -$3.15M |
|
3737
CALL
BlackLine
BL
$1.92B
| $2.31M | ﹤0.01% |
53,300
-13,600
| -20% | -$575K |
|
3738
PUT
Halozyme
HALO
$12B
| $2.31M | ﹤0.01% |
137,000
+14,900
| +12% | +$282K |
|
3739
iShares MSCI ACWI ETF
ACWI
$33.3B
| $2.31M | ﹤0.01% |
32,427
+19,827
| +157% | +$1.44M |
|
3740
CALL
MiMedx Group
MDXG
$656M
| $2.31M | ﹤0.01% |
360,700
-92,700
| -20% | -$660K |
|
|
OCLR
3741
PUT
DELISTED
Oclaro Inc.
OCLR
| $2.31M | ﹤0.01% |
258,100
+22,900
| +10% | +$200K |
|
3742
CALL
Belden
BDC
$4.5B
| $2.3M | ﹤0.01% |
37,700
+30,000
| +390% | +$1.84M |
|
3743
CALL
Impinj
PI
$5.2B
| $2.3M | ﹤0.01% |
104,200
-48,700
| -32% | -$824K |
|
3744
CALL
Vanguard Morningstar Small-Cap Growth ETF
VBK
$24B
| $2.3M | ﹤0.01% |
13,100
-10,300
| -44% | -$1.77M |
|
3745
Tronox
TROX
$862M
| $2.3M | ﹤0.01% |
+116,960
| New | +$2.18M |
|
|
DLPH
3746
CALL
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $2.3M | ﹤0.01% |
50,600
-35,700
| -41% | -$1.78M |
|
|
AUY
3747
CALL
DELISTED
Yamana Gold, Inc.
AUY
| $2.3M | ﹤0.01% |
792,300
+628,400
| +383% | +$1.83M |
|
3748
ProShares UltraShort Silver
ZSL
$63.7M
| $2.3M | ﹤0.01% |
416
+317
| +320% | +$1.66M |
|
|
CNSL
3749
CALL
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $2.3M | ﹤0.01% |
185,800
+48,200
| +35% | +$562K |
|
3750
PUT
Gyre Therapeutics
GYRE
$699M
| $2.29M | ﹤0.01% |
26,213
+2,453
| +10% | +$430K |
|
Similar funds
Jeff Yass's Q2 2018 Portfolio in Review
As of Q2 2018, Jeff Yass held 11,136 positions worth $291B, up 3.8% from $281B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass's Q2 2018 filing shows 1,911 new, 3,840 increased, 3,666 reduced and 1,619 closed positions. Its largest new stake was iShares Core MSCI EAFE ETF: 4,732,803 shares worth $300M. The largest sale was Meta Platforms (Facebook), an estimated $1.5B.
By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 92% a quarter earlier, followed by Technology and Financials.
- Jeff Yass's largest Q2 2018 buy was iShares Core MSCI EAFE ETF: 4,732,803 shares worth $300M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q2 2018, an estimated $696M increase.
- Jeff Yass's biggest Q2 2018 reduction was Meta Platforms (Facebook), cutting an estimated $1.5B.
- Jeff Yass fully exited iShares 0-1 Year Treasury Bond ETF in Q2 2018, selling an estimated $341M.
- Jeff Yass's ten largest holdings make up 26% of its $291B portfolio in Q2 2018.
- Jeff Yass opened 1,911 new positions and closed 1,619 in Q2 2018.
- Jeff Yass's portfolio value rose 3.8% quarter-over-quarter to $291B.
Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.